Past performance does not predict future results. Informational only, not investment advice.
Plus Therapeutics has a revenue-generating diagnostic (CNSide) with strong adoption at 120+ cancer centers and major payer coverage, plus a high-potential pipeline asset (REYOBIQ) in late-stage trials. With insiders aggressively buying and a $7.25 analyst target against a $0.55 current price, the risk-reward is asymmetric through 2026.
Plus Therapeutics is entering a rare convergence of catalysts: medical conference data on LM trial, Phase 2 enrollment completion, FDA meeting minutes, and CNside geographic expansion. These milestones create regulatory clarity and reduce uncertainty around a registrational pathway, positioning PSTV for significant valuation repricing.
Plus Therapeutics announced continued progress on the commercial launch of CNSide's CSF tumor cell enumeration diagnostic test, signaling operational execution and revenue potential that should drive upside in the stock.
End of results.